The U.S. Food and Drug Administration (FDA) has approved Ferring Pharmaceuticals’ drug product manufacturing hub in Parsippany, NJ, for its intravesical non-replicating gene therapy ADSTILADRIN (nadofaragene firadenovec-vncg). The approval expands Ferring’s manufacturing capabilities to three sites dedicated to bringing ADSTILADRIN to patients and secures a final $200 million payment from Royalty Pharma as part of a royalty-based financing agreement announced in 2023. ADSTILADRIN is the fi...